<a href="https://pro.campus.sanofi/dam/jcr:9e0d6f97-2ebb-4422-92ab-569b89c7dfe0/praluent%C2%AE-(alirocumab)-prescribing-information-(uk)document.pdf" target="_blank">Praluent® (alirocumab) Prescribing Information (PI link here)</a>

Intensive and sustained LDL-C reduction?1 It’s Praluent® of course

GENERAL-MEDICINES

PRALUENT

DYSLIPIDEMIA

CARDIOLOGY

Praluent® (alirocumab): A PCSK9i That Ticks All the Boxes: Discover key data from the ODYSSEY OUTCOMES trial

Managing LDL-C in post-ACS patients may remain one of cardiology's most persistent challenges — with evidence showing the majority of very high-risk patients are not reaching the ESC/EAS guideline recommended goals on statins alone.6,7
Explore the key data from the ODYSSEY OUTCOMES* trial (N=18,924), which evaluated alirocumab (Praluent®) after acute coronary syndrome. Across the trial, PRALUENT® delivered intensive and sustained LDL-C reduction1, resulting in a significant decrease in major adverse cardiovascular events (MACE)2. In a post hoc analysis§, PRALUENT® also demonstrated its ability to help patients reach LDL-C goals, with 95% of ACS patients achieving LDL-C target levels.6
Key data highlights covered:&nbsp;

LDL-C reduction relative to placebo at 4 months‡‡ - sustained at &gt;54% over 4 years1

Risk reduction in MACE 1,2&nbsp;&nbsp;&nbsp;
 
 (HR 0.85; 95% CI 0.78–0.93;&nbsp;&nbsp;
 
 P=0.0003; ARR 2.0% at 4&nbsp;&nbsp;
 
 years††)&nbsp;&nbsp;
 
 &nbsp;

Long-term safety profile3‡

Patient satisfaction:
Beyond efficacy, the self-administration device was designed with the patient in mind: a hidden needle, a button-free autoinjector, and a dose delivered in ≤20 seconds. 2,4 The ease of usability is also supported by real-world data from the ODYSSEY APRISE† and SYDNEY device study**, indicating patients felt satisfied and confident self-injecting at home.&nbsp;

Patient satisfaction score across&nbsp;
 
 all assessments, indicating&nbsp;
 
 patients felt satisfied and&nbsp;
 
 confident self-injecting at home4

Patient adherence over a mean&nbsp;
 
 72.4-week treatment duration5

PRALUENT® offers flexible dosing to meet individual patient needs — the usual starting dose for PRALUENT® is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (&gt;60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2
If you have any questions or would like further information about Praluent®, please contact Sanofi's customer care team at <a href="mailto:SanofiCares@sanofi.com" target="_blank">SanofiCares@sanofi.com</a>.
Important safety information:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 
 The most common adverse reactions, at recommended doses, are local injection site reactions (6.1%), upper respiratory tract signs and symptoms (2.0%), and pruritus (1.1%). Most common adverse reactions leading to treatment discontinuation in patients treated with alirocumab were local injection site reactions.2
For more information on Praluent® adverse events please see SmPC.

<h3>Praluent®</h3>
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

<h3>Patient Website</h3>
Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Footnotes:

References:

Abbreviations:

REZUROCK▼ (belumosudil) is intended for HCPs practising in the United Kingdom.

<h2>PATIENT CASE STUDY</h2>
This case study was provided by Dr Maria Losa Maroto from Queen Elizabeth Hospital NHS Trust, Birmingham and provides an overview of a 42-year-old female patient who suffered with severe lung cGVHD. This patient experienced notable improvements in lung function and overall quality of life after starting REZUROCK treatment, following previous lines of therapy including ECP.

The slide deck above may not display properly on some devices, please access the PDF version of the slides using the button below

<h2>Discover more patient case studies</h2>

Discover all our cGVHD patient case studies&nbsp;

Discover case studies presented at EBMT

Severe Lung GVHD: A Real World Case Study

REZUROCK®▼ (belumosudil) Prescribing Information UK

TRANSPLANT---CORE

REZUROCK

TRANSPLANT

<a href="${link:{uuid:{2a02177b-5764-4cb8-98b6-34b9445e0571},repository:{dam},path:{/Portal/UK/Prescribing-Information/Toujeo-PI-UK.pdf}}}">Toujeo (insulin glargine 300U/mL) Prescribing Information</a>

<h2 style="text-align:center;">A Century of Insulin Experience</h2>

For over 100 years, Sanofi has been committed to the development and production of insulin therapies for people living with diabetes1. Our long-standing heritage in diabetes care has enabled us to build extensive expertise in insulin manufacturing and supply chain management.

<h3 style="text-align:center;">Our Commitment to Toujeo® Insulin Supply in the UK</h3>
Sanofi recognises the clinical importance of maintaining a reliable insulin supply for patients who depend on Toujeo®. We maintain robust contingency plans and strategic inventory management to help ensure continuity of supply across our insulin portfolio.

<h3 style="text-align:center;">Investment in Manufacturing Capabilities</h3>
We continue to invest in our global manufacturing network to enhance production capacity and implement technological advancements. Our manufacturing facilities operate to rigorous quality standards, with regular monitoring and evaluation to maintain compliance with international regulatory requirements.

DIABETES-CORE

OTHER-DIABETES-TOPICS

TYPE-2-DIABETES

TYPE-1-DIABETES

DIABETES

Learn more about Toujeo®

<h2 style="text-align:center;">Evaluating the Environmental Impact Across the Pen Manufacturing Chain</h2>
Toujeo®(insulin glargine U300) pens have been developed with a strong focus on environmental sustainability, supported by a rigorous ISO-certiﬁed Life Cycle Assessment (LCA) conducted in 2024.1 This assessment evaluated the environmental footprint of the product across its entire lifecycle—from raw material sourcing to manufacturing, distribution, use, and disposal. The eco-design approach has led to the below environmental gains, by optimising each step of Toujeo's product lifecycle:1

A key milestone in this journey is the transition to 100% renewable electricity across all insulin manufacturing facilities, reinforcing our commitment to sustainable healthcare delivery.1

<h2 style="text-align:center;">RePen Recycling Scheme</h2>
Sanofi is committed to reducing the environmental impact of diabetes care. The RePen recycling scheme allows patients to return used insulin pens for responsible disposal and recycling.
For more information about the RePen recycling programme and to find your nearest participating location, please visit <a href="https://www.mysanofiinsulin.co.uk/repen/">mysanofiinsulin.co.uk/repen</a>

<h2>Dedicated Support</h2>
Our UK-based customer care team is available to provide support and information regarding our insulin products via <a href="mailto:sanoficares@sanofi.com" target="_blank">sanoficares@sanofi.com</a>.
Our team can provide information on product availability, storage recommendations, and address general enquiries about our insulin products.

Toujeo®

Lantus®

Reference:

Frequently Asked Questions (FAQs)

MAT-XU-2504557 (v4.0) | Date of preparation: July 2026

Sanofi's Commitment to Diabetes with Insulin Supply in the UK

A hub for healthcare professionals to discover and find information on our medicines, therapies and vaccines.

Welcome to Sanofi Campus UK

OUT-OF-TAXONOMY

GENERAL-TOPICS

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v7.0) - Date of Preparation: July 2025

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Review the materials in your cart before checkout.

Browse and order materials for your practice.

Filters

Materials

Cart

Checkout

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Welcome to Sanofi Campus UK

The latest content

Praluent® (alirocumab): A PCSK9i That Ticks All the Boxes: Discover key data from the ODYSSEY OUTCOMES trial

Severe Lung GVHD: A Real World Case Study

Sanofi's Commitment to Diabetes with Insulin Supply in the UK

Quick Links

Register for access to additional content

Payor Portal